In older patients (≥65 years) anticoagulated for acute VTE, the incidence of major bleeding was 8.5 per 100 patient-years and clinically relevant nonmajor bleeding was 13.4 per 100 patient-years.
Cohort (n=981)
Yes
Older patients anticoagulated for acute VTE experience a high incidence of major and clinically relevant nonmajor bleeding, which carries a substantial clinical burden including high rates of hospitalization and mortality.
Older patients anticoagulated for venous thromboembolism (VTE) have an increased risk of bleeding compared with younger patients. Little is known about the clinical impact of anticoagulation-related bleeding in this growing patient group. To prospectively assess the incidence, clinical impact, and predictors of bleeding in older patients anticoagulated for VTE, we analyzed 981 patients aged ≥65 years with acute VTE in a prospective multicenter cohort. Eight-eight percent were anticoagulated with vitamin K antagonists. Outcomes were the occurrence of major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) event during the initial anticoagulation period up to 36 months. We described the incidence and clinical impact of bleeding and examined the association between risk factors and time to a first bleeding using competing risk regression; 100 MB and 125 CRNMB events occurred during follow-up. The incidence of MB and CRNMB was 8.5 (95% confidence interval CI, 7.0-10.4) and 13.4 events (95% CI, 11.4-15.7) per 100 patient-years, respectively. In patients with MB, 79% required hospitalization, 18% required surgical intervention, and 19% required permanent discontinuation of anticoagulation; 15% of MB were intracranial and 6% were fatal. After adjustment, active cancer (subhazard ratio SHR, 1.81; 95% CI, 1.12-2.93) and low physical activity (SHR, 1.88; 95% CI, 1.19-2.98) were associated with MB and high risk of falls with CRNMB (SHR, 2.04; 95% CI, 1.39-3.00). Older patients anticoagulated for VTE had a high incidence of MB and CRNMB, and these bleeding episodes caused a great burden of disease. Physicians should carefully weigh the risks/benefits of extended anticoagulation in the older population with VTE.
Ferrazzini et al. (Tue,) conducted a cohort in acute venous thromboembolism (n=981). Anticoagulation was evaluated on Major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB). In older patients (≥65 years) anticoagulated for acute VTE, the incidence of major bleeding was 8.5 per 100 patient-years and clinically relevant nonmajor bleeding was 13.4 per 100 patient-years.